Avacta Group PLC AVCTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.96
- Day Range
- $0.94–0.94
- 52-Week Range
- $0.75–1.23
- Bid/Ask
- $0.59 / $1.43
- Shares Outstanding
- 456.96M
- Market Cap
- $425.21M
- Volume/Avg
- 3,300 / 6,368
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,687.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://avacta.com
Valuation
|
Metric
|
AVCTF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 85.77 |
Price/Sales | 2,687.52 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVCTF
|
|---|---|
Quick Ratio | 0.95 |
Current Ratio | 0.95 |
Interest Coverage | −4.86 |
Quick Ratio
AVCTF
Profitability
|
Metric
|
AVCTF
|
|---|---|
Return on Assets (Normalized) | −112.85% |
Return on Equity (Normalized) | −1,601.77% |
Return on Invested Capital (Normalized) | −150.39% |
Return on Assets
AVCTF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<G>xn@j | LOCK|N%K@ | $128B | |||
| Moderna Inc
MRNA
| LOCK|qH@GL< | LOCK|GkJ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&&L>w? | LOCK|s!G>% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|Ts#Djh@ | LOCK|z? | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<Y?#h>G | LOCK|<p | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vq?G&g% | LOCK|DvP? | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Byw>!&h | LOCK|fj<D | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&t&DRQq | LOCK|>& | $24B | |||
| Incyte Corp
INCY
| LOCK|&YpFrr | LOCK|!< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&!N!>N& | LOCK|R> | $15B |
United States